Back to News
Market Impact: 0.42
Vanda Reports Positive Phase 3 Results For HETLIOZ In Delayed Sleep-Wake Phase Disorder; Stock Up
Source: Nasdaq
Healthcare & BiotechProduct Launches
Vanda Pharmaceuticals announced positive topline results from a pivotal Phase 3 trial of HETLIOZ (tasimelteon) in adults with Delayed Sleep-Wake Phase Disorder. The positive late-stage data could support a potential expansion of HETLIOZ's addressable market and is a meaningful catalyst for VNDA, although no efficacy or safety figures were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
VNDA0.82
More News
- Google rolls out Gemini 4 Argon, its most advanced AI model
- Huawei unveils Mate 90 phones, leans on homegrown chip design to offset US curbs
- Meta stock enjoys best month since 2022 on AI momentum
- Bloomberg Tech: OpenAI Seeks $30B as Trump Backs Safety Audits
- OpenAI’s $30B Bet, Trump’s AI Safety Shift and Apple’s Next Act
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Run Cost-Controlled Financial Research in AllMind Agent Studio